A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis
Study of BLU-263 in Patients with Indolent Systemic Mastocytosis (ISM) or Monoclonal Mast Cell Activation Syndrome (mMCAS)
Sponsor: Blueprint Medicines Corporation
Enrolling: Male and Female Patients
IRB Number: AAAT8963
U.S. Govt. ID: NCT04910685
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: You are being asked to participate in this study because you have indolent SM (ISM) or because you have Monoclonal mast cell activation syndrome (mMCAS). Currently, there are no available targeted therapies for patients with ISM or mMCAS. The study will test the drug BLU-263. BLU-263 is a new study drug that is being developed for treating people like you, with ISM and/or mMCAS. BLU-263 is not yet approved for treating ISM and/or mMCAS by the Food and Drug Administration (FDA). BLU-263 is the first study drug in a group of drugs that prevents a specific DNA change called KIT D816V. The goal is to find a safe and acceptable dose in people with ISM and/or mMCAS and to find how the body processes the study drug at different dose levels. The drug company also wants to find out what effects, good and bad, BLU-263 has on participants in this study.
Joseph Jurcic, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with Indolent Systemic Mastocytosis (ISM) and/or Monoclonal Mast Cell Activation Syndrome (mMCAS)? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator